POLBF
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.01 | $0 | -$3M |
| 2025 Q2 | -0.00 | $0 | -$2M |
| 2024 Q4 | -0.01 | $0 | -$2M |
| 2024 Q2 | -0.00 | $0 | -$2,262 |
| 2023 Q4 | -0.00 | $0 | -$2M |
| 2023 Q2 | -0.00 | $0 | -$2M |
| 2022 Q4 | -0.01 | $0 | -$3M |
| 2022 Q2 | -0.00 | $0 | -$2M |